Competing interests
RS, MCN
CORBUS
WAS: Received consulting fees and grants from AbbVie, GSK, Novartis, Roche, and Sanofi; speakers bureau for AbbVie, Chugai, GSK, Novartis, Roche, and Sanofi; has been an investigator on clinical trials for AbbVie, GSK, Novartis, and Sanofi. BD: Consultant for Sanofi and Roche Chugai; speakers bureau for Roche Chugai and Cipla; received grant/research support from Sanofi, Roche, and AbbVie. JS, YX, and YL: Employees of Sanofi and may hold stocks or stock options in the company. AG: Employee and shareholder of Regeneron Pharmaceuticals, Inc at the time of the conduct of study. MCN and BA: Employees and shareholders of Regeneron Pharmaceuticals, Inc. SHU: Consultant for Sanofi, Kiniksa, and Janssen; received grant/research support from Genentech. SLM: Consultant on behalf of her institution for Roche/Chugai, Sanofi, AbbVie, and AstraZeneca; received speaker fees for her institution from Pfizer and Vifor; received grant/research support from Vifor – all outside the submitted work; received support from Roche/Chugai to attend EULAR 2019 and from Pfizer to attend ACR Convergence 2021;  SLM is supported by the NIHR Biomedical Research Centre. MAG: Received grant/research support from AbbVie, MSD, Janssen, and Roche; received consultation fees/participation from company-sponsored speakers bureaus tied to AbbVie, Pfizer, Roche, Sanofi, Eli Lilly, Celgene, and MSD. RS: Consultant for Sanofi, GSK, Novartis, ChemoCentryx, Roche-Genentech, and AbbVie; received grant/research support from GSK, ChemoCentryx, Corbus, InflaRx, and Boehringer Ingelheim. KJW: Paid instructor for ChemoCentryx; received grant/research support from Eli Lilly, Kiniksa, and GSK; received consulting fees from Sanofi. PMV: Received speaker, advisory fees, and/or research support from Roche, MSD, AbbVie, Sanofi, Grünenthal, Amgen, Chugai, BMS, Janssen, and Drossapharm. FB: Received grants and personal fees from Horizon Therapeutics, AbbVie, and Sanofi; received grants from Mundipharma; received grants, personal fees, and non-financial support from Roche; received personal fees from Galapagos outside the submitted work. JHS: Consultant for and received research funds from Roche.